{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:00:23Z","timestamp":1790848823811,"version":"4.1.0"},"reference-count":148,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Most patients with colorectal liver metastases (CRLM) present with disease beyond upfront technical resectability. Advances in systemic therapy, surgical technique, and liver-directed therapies have expanded the proportion of patients who can achieve curative-intent treatment, yet substantial heterogeneity in practice persists. This review provides a structured synthesis of current management strategies for borderline resectable, initially unresectable, and never resectable CRLM. Methods: A structured literature search of PubMed\/MEDLINE, Embase, Scopus and the Cochrane Library was performed to identify studies published between 2000 and 2026 using the eligibility criteria described in Part 1 of this review. Findings were synthesized narratively across systemic, surgical, and liver-directed treatment strategies. Results: Future liver remnant augmentation through regenerative procedures offers higher rates of conversion to resection in borderline cases. Conversion chemotherapy enables secondary resection in 12\u201335% of initially unresectable patients, with regimen selection guided by RAS\/BRAF status, primary tumor sidedness, and performance status; however, most pivotal trials were designed for the broader metastatic colorectal cancer population, with conversion to resection rarely serving as the primary endpoint. For never resectable liver-only disease, liver transplantation demonstrates survival advantage in highly selected patients and iterative local therapy remains an area of active investigation. Across all settings, achieving complete local treatment remains the strongest determinant of long-term survival. Conclusions: Management of complex CRLM requires individualized, multidisciplinary decision-making with repeated reassessment of resectability throughout treatment. The evidence is constrained by heterogeneous resectability definitions, reliance on trials not designed for CRLM-specific endpoints, and limited data on several emerging strategies. Standardized eligibility frameworks and CRLM-specific trial designs are needed to advance the field.<\/jats:p>","DOI":"10.3390\/cancers18193169","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:38:16Z","timestamp":1790847496000},"page":"3169","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Contemporary Review of Resectability and Treatment Strategies for Colorectal Liver Metastases: Part 2\u2014Advanced Surgical Techniques, Conversion Strategies, and the Expanding Boundaries of Treatment"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6304-4690","authenticated-orcid":false,"given":"Jennifer A.","family":"Kalil","sequence":"first","affiliation":[{"name":"Cancer Research Program, Research Institute of the McGill University Health Center (RI-MUHC), Montreal, QC H4A 3J1, Canada"},{"name":"Department of Surgery, McGill University Health Center, Montreal, QC H4A 0B1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-5449","authenticated-orcid":false,"given":"Ren\u00e9","family":"Adam","sequence":"additional","affiliation":[{"name":"Henri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris-Saclay University, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-8484","authenticated-orcid":false,"given":"Nicholas","family":"Meti","sequence":"additional","affiliation":[{"name":"Gerald Bronfman Department of Oncology, McGill University Health Center, Montreal, QC H4A 0B1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-8136","authenticated-orcid":false,"given":"Peter","family":"Metrakos","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Research Institute of the McGill University Health Center (RI-MUHC), Montreal, QC H4A 3J1, Canada"},{"name":"Department of Surgery, McGill University Health Center, Montreal, QC H4A 0B1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kalil, J.A. A contemporary review of resectability and treatment strategies for colorectal liver metastases: Part 1\u2014Diagnosis, defining resectability, and management of upfront resectable and synchronous disease, Cancers 2026, to be submitted.","DOI":"10.3390\/cancers18193165"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","article-title":"Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure?","volume":"27","author":"Adam","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00270-012-0440-y","article-title":"Portal vein embolization before liver resection: A systematic review","volume":"36","author":"Bipat","year":"2013","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/bjs\/znaa149","article-title":"Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis","volume":"108","author":"Heil","year":"2021","journal-title":"Br. J. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00000658-200012000-00006","article-title":"Two-Stage Hepatectomy- A Planned Strategy to Treat Irresectable Liver Tumors","volume":"232","author":"Adam","year":"2000","journal-title":"Ann. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jamaoncol.2024.5174","article-title":"First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial","volume":"11","author":"Bond","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs. Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","article-title":"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): Results from a multicentre, open-label, prospective, randomised controlled trial","volume":"404","author":"Adam","year":"2024","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102056","DOI":"10.1016\/j.suronc.2024.102056","article-title":"Debulking hepatectomy for colorectal liver metastasis: Analysis of risk factors for progression free survival","volume":"55","author":"Mazzotta","year":"2024","journal-title":"Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kim, J.S., Kim, H., Lee, S.Y., Han, Y.D., Han, K., Min, B.S., Kim, M.D., Won, J.Y., Beom, S.H., and Shin, S.J. (2023). Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: A randomized phase II study\u2014(NCT05103020)\u2014Study protocol. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11085-w"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101868","DOI":"10.1016\/j.gassur.2024.10.023","article-title":"Optimal treatment strategies for borderline resectable liver metastases from colorectal cancer","volume":"29","author":"Varty","year":"2025","journal-title":"J. Gastrointest. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12254-016-0308-y","article-title":"ASCO 2016\u2014Update colorectal liver metastases","volume":"10","author":"Kaczirek","year":"2017","journal-title":"Memo"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12957-019-1641-5","article-title":"Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases","volume":"17","author":"Ichida","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1245\/s10434-010-1166-1","article-title":"Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases","volume":"17","author":"Kishi","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102926","DOI":"10.1016\/j.ctrv.2025.102926","article-title":"EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases","volume":"136","author":"Bregni","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_18","first-page":"e240029","article-title":"Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1470-2045(19)30798-3","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): Long-term results of a multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Bridgewater","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Audard","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/bjs.10572","article-title":"Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases","volume":"104","author":"Zhao","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.hpb.2016.03.001","article-title":"Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases","volume":"18","author":"Khoo","year":"2016","journal-title":"HPB"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/sj.bjc.6603670","article-title":"Safe liver resection following chemotherapy for colorectal metastases is a matter of timing","volume":"96","author":"Welsh","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00534-008-0016-z","article-title":"Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases","volume":"16","author":"Khan","year":"2009","journal-title":"J. Hepato-Biliary-Pancreat. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1007\/s00330-016-4291-9","article-title":"Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: The liver venous deprivation technique","volume":"26","author":"Guiu","year":"2016","journal-title":"Eur. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00270-024-03743-8","article-title":"CIRSE Standards of Practice on Portal Vein Embolization and Double Vein Embolization\/Liver Venous Deprivation","volume":"47","author":"Bilhim","year":"2024","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"znae087","DOI":"10.1093\/bjs\/znae087","article-title":"Liver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: Mid-term survival analysis of the multicentre DRAGON 0 cohort","volume":"111","author":"Korenblik","year":"2024","journal-title":"Br. J. Surg."},{"key":"ref_28","first-page":"101284","article-title":"Safety and efficacy of combined portal and hepatic vein embolisation in patients with colorectal liver metastases (DRAGON1): A multicentre, single-arm clinical trial","volume":"53","author":"Korenblik","year":"2025","journal-title":"Lancet Reg. Health\u2014Eur."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of Surgical Complications","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chaouch, M.A., Mazzotta, A., da Costa, A.C., Hussain, M.I., Gouader, A., Krimi, B., Panaro, F., Guiu, B., Soubrane, O., and Oweira, H. (2023). A systematic review and meta-analysis of liver venous deprivation versus portal vein embolization before hepatectomy: Future liver volume, postoperative outcomes, and oncological safety. Front Med., 10.","DOI":"10.3389\/fmed.2023.1334661"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.hpb.2017.01.008","article-title":"Feasibility, safety and efficacy of two-stage hepatectomy for bilobar liver metastases of colorectal cancer: A LiverMetSurvey analysis","volume":"19","author":"Regimbeau","year":"2017","journal-title":"HPB"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107267","DOI":"10.1016\/j.ejso.2023.107267","article-title":"Factors of oncological failure in two stage hepatectomy for colorectal liver metastases","volume":"50","author":"Nassar","year":"2024","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/SLA.0b013e31824856f5","article-title":"Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings","volume":"255","author":"Schnitzbauer","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ejso.2022.11.010","article-title":"Two stage hepatectomy (TSH) versus ALPPS for initially unresectable colorectal liver metastases: A systematic review and meta-analysis","volume":"49","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.suronc.2020.01.010","article-title":"Technical modifications and outcomes after Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) for primary liver malignancies: A systematic review","volume":"33","author":"Baili","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"110217","DOI":"10.1016\/j.surg.2026.110217","article-title":"Outcomes following 2-stage hepatectomy: Systematic review and meta-analysis exploring liver regeneration strategies","volume":"195","author":"Helg","year":"2026","journal-title":"Surgery"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamasurg.2020.0802","article-title":"Review of the Southampton Consensus Guidelines for Laparoscopic Liver Surgery","volume":"155","author":"Ejaz","year":"2020","journal-title":"JAMA Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/SLA.0000000000002353","article-title":"Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial","volume":"267","author":"Fretland","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/M20-4011","article-title":"Long-Term Oncologic Outcomes After Laparoscopic Versus Open Resection for Colorectal Liver Metastases: A Randomized Trial","volume":"174","author":"Aghayan","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105530","DOI":"10.3748\/wjg.v31.i18.105530","article-title":"Laparoscopic associating liver partition and portal vein ligation for staged hepatectomy for colorectal liver metastases: A single-center experience","volume":"31","author":"Zheng","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1007\/s00464-026-13093-w","article-title":"Advanced robotic liver surgery","volume":"40","author":"Mascherini","year":"2026","journal-title":"Surg. Endosc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1002\/cncr.28203","article-title":"Near-infrared fluorescence-guided resection of colorectal liver metastases","volume":"119","author":"Schaafsma","year":"2013","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/SLA.0000000000005121","article-title":"Liver Venous Deprivation or Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy?: A Retrospective Multicentric Study","volume":"274","author":"Chebaro","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/SLA.0000000000002511","article-title":"ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial)","volume":"267","author":"Sandstrom","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.hpb.2024.01.002","article-title":"Efficacy and perioperative safety of different future liver remnant modulation techniques: A systematic review and network meta-analysis","volume":"26","author":"Bozkurt","year":"2024","journal-title":"HPB"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00268-017-4181-6","article-title":"Operative Results and Oncologic Outcomes of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Two-Stage Hepatectomy (TSH) in Patients with Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis","volume":"42","author":"Moris","year":"2018","journal-title":"World J. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.surg.2017.05.022","article-title":"Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: Liver volume overestimates liver function","volume":"162","author":"Olthof","year":"2017","journal-title":"Surgery"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.surg.2018.11.004","article-title":"Functional and volumetric assessment of liver segments after portal vein embolization: Differences in hypertrophy response","volume":"165","author":"Rassam","year":"2019","journal-title":"Surgery"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ejso.2016.03.020","article-title":"Drop-out between the two liver resections of two-stage hepatectomy. Patient selection or loss of chance?","volume":"42","author":"Torzilli","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11605-022-05551-2","article-title":"Liver Venous Deprivation Versus Portal Vein Embolization Before Major Hepatectomy for Colorectal Liver Metastases: A Retrospective Comparison of Short- and Medium-Term Outcomes","volume":"27","author":"Cassese","year":"2023","journal-title":"J. Gastrointest. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101812","DOI":"10.1016\/j.suronc.2022.101812","article-title":"Liver venous deprivation versus associating liver partition and portal vein ligation for staged hepatectomy for colo-rectal liver metastases: A comparison of early and late kinetic growth rates, and perioperative and oncological outcomes","volume":"43","author":"Cassese","year":"2022","journal-title":"Surg. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.hpb.2025.11.011","article-title":"Liver venous deprivation (LVD) or ALPPS in the treatment of colorectal liver metastasis (CRLM): A comparison of oncological outcome","volume":"28","author":"Boubaddi","year":"2026","journal-title":"HPB"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.hpb.2026.04.464","article-title":"ALPPS vs. PVE vs. LVD: Selecting the optimal liver hypertrophy method for patients with liver malignancies, before undergoing large scale hepatectomy; A systematic review and meta-analysis","volume":"28","author":"Fotiadou","year":"2026","journal-title":"HPB"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/annonc\/mdh217","article-title":"Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients","volume":"15","author":"Pozzo","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ejso.2021.02.019","article-title":"Conversion therapy in patients with colorectal liver metastases","volume":"47","author":"Villard","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"644\u2013657; discussion 657\u2013648","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s10147-018-01393-8","article-title":"mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): A multicenter phase II trial comprising the final analysis for survival","volume":"24","author":"Yasuno","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/jhbp.747","article-title":"Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): Long-term results of survival","volume":"27","author":"Okuno","year":"2020","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdu580","article-title":"Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: The OLIVIA multinational randomised phase II trial","volume":"26","author":"Gruenberger","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Wang, D.S., Ren, C., Li, S.S., Fong, W.P., Wu, X.J., Xiao, J., Li, B.K., Zheng, Y., Ding, P.R., and Chen, G. (2024). Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS\/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS Med., 21.","DOI":"10.1371\/journal.pmed.1004389"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest","volume":"25","author":"Falcone","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12029-023-00983-8","article-title":"Prognostic Effect of Performance Status on Outcomes of Patients with Colorectal Cancer Receiving First-Line Chemotherapy: A Meta-analysis","volume":"55","author":"Colloca","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12957-017-1306-1","article-title":"Significance of poor performance status after resection of colorectal liver metastases","volume":"16","author":"Eriksson","year":"2018","journal-title":"World J. Surg. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1200\/JCO.2005.07.740","article-title":"Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study","volume":"23","author":"Alberts","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/07357907.2015.1104689","article-title":"XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis","volume":"34","author":"Guo","year":"2016","journal-title":"Cancer Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","article-title":"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)","volume":"94","author":"Souglakos","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","article-title":"Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","article-title":"PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","article-title":"Final analysis of the randomised PEAK trial: Overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma","volume":"32","author":"Rivera","year":"2017","journal-title":"Int. J. Color. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1200\/JCO.22.00839","article-title":"Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS\/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO","volume":"40","author":"Rossini","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO-25-01337","article-title":"Upfront Modified FOLFOXIRI Plus Panitumumab for RAS\/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study","volume":"44","author":"Conca","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial","volume":"38","author":"Tang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(23)00219-X","article-title":"First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): An open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group","volume":"24","author":"Bond","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: A randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Shiu","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Hitre","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/1751-2980.12063","article-title":"Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A meta-analysis","volume":"14","author":"Xu","year":"2013","journal-title":"J. Dig. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","article-title":"Mutational Analysis of Patients With Colorectal Cancer in CALGB\/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome","volume":"37","author":"Innocenti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study","volume":"40","author":"Lenz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","article-title":"Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer","volume":"33","author":"Yaeger","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","article-title":"Impact of primary (1\u00ba) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB\/SWOG 80405 (Alliance)","volume":"34","author":"Venook","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_91","first-page":"CD012757","article-title":"Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases","volume":"8","author":"Swierz","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/bjs\/znaa155","article-title":"Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: Randomized clinical trial","volume":"108","author":"Liu","year":"2021","journal-title":"Br. J. Surg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","article-title":"Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection","volume":"59","author":"Vouche","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10456-026-10049-5","article-title":"Portal vein embolization versus radiation lobectomy as pre-treatment for major liver resection for colorectal liver metastases: Functional assessment of the future liver remnant","volume":"29","author":"Ramdhani","year":"2026","journal-title":"Angiogenesis"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1245\/s10434-016-5418-6","article-title":"Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study","volume":"24","author":"Dhir","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"Boige","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jso.24898","article-title":"Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential","volume":"117","author":"Pak","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"znae089","DOI":"10.1093\/bjs\/znae089","article-title":"Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: Phase II feasibility study","volume":"111","author":"Krul","year":"2024","journal-title":"Br. J. Surg."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.dld.2021.12.012","article-title":"Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +\/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49","volume":"54","author":"Pernot","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.radonc.2018.06.035","article-title":"Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review","volume":"129","author":"Petrelli","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ijrobp.2020.11.045","article-title":"The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases","volume":"109","author":"Schillemans","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Moskalenko, A., Chernykh, M., Ichshanov, D., Malinina, K., Ikonnikova, A., and Lyadov, V. (2025). Stereotactic Body Radiotherapy of Colorectal Cancer Oligometastases to the Liver: Three Years Follow-Up. Cancers, 17.","DOI":"10.3390\/cancers17172823"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ijrobp.2017.12.014","article-title":"Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases","volume":"100","author":"Jackson","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review","volume":"145","author":"Lee","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1001\/jama.2009.1755","article-title":"Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases","volume":"302","author":"Chun","year":"2009","journal-title":"JAMA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1148\/radiol.2017161619","article-title":"Use of Imaging to Predict Complete Response of Colorectal Liver Metastases after Chemotherapy: MR Imaging versus CT Imaging","volume":"284","author":"Park","year":"2017","journal-title":"Radiology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2006.05.8727","article-title":"Complete response of colorectal liver metastases after chemotherapy: Does it mean cure?","volume":"24","author":"Benoist","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11605-021-05164-1","article-title":"Imaging of Colorectal Liver Metastasis","volume":"26","author":"Baghdadi","year":"2022","journal-title":"J. Gastrointest. Surg."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"110577","DOI":"10.1016\/j.ejso.2025.110577","article-title":"EORTC1527\/JCOG1609INT\/ESSO002: DW-MRI Assessment of Disappearing Liver Metastasis to Improve Surgical Planning (DREAM)","volume":"51","author":"Kataoka","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/bjs\/znaa145","article-title":"Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: Prospective study","volume":"108","author":"Isoniemi","year":"2021","journal-title":"Br. J. Surg."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00423-023-03082-1","article-title":"Survival after combined resection and ablation is not inferior to that after resection alone, in patients with four or more colorectal liver metastases","volume":"408","author":"Amygdalos","year":"2023","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1245\/s10434-023-13751-6","article-title":"Rates and Patterns of Recurrence After Microwave Ablation of Colorectal Liver Metastases: A Per Lesion Analysis of 416 Tumors in the Era of 2.45 GHz Generators","volume":"30","author":"Karagkounis","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00432-018-2692-7","article-title":"Liver metastases from colorectal cancer: Propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation","volume":"144","author":"Franzese","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S1470-2045(22)00506-X","article-title":"Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: A retrospective study and meta-analysis","volume":"23","author":"Ecker","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/SLA.0b013e3181b4539b","article-title":"Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients","volume":"250","author":"Pulitano","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.surg.2022.10.019","article-title":"Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis","volume":"173","author":"Sutton","year":"2023","journal-title":"Surgery"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ejso.2014.03.012","article-title":"Selecting patients for a second hepatectomy for colorectal metastases: An systemic review and meta-analysis","volume":"40","author":"Luo","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.hpb.2019.11.013","article-title":"The impact of hepatic arterial infusion pump chemotherapy on hepatic recurrences and survival in patients with resected colorectal liver metastases","volume":"22","author":"Buisman","year":"2020","journal-title":"HPB"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1245\/s10434-020-08776-0","article-title":"Recurrence After Liver Resection of Colorectal Liver Metastases: Repeat Resection or Ablation Followed by Hepatic Arterial Infusion Pump Chemotherapy","volume":"28","author":"Buisman","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"115154","DOI":"10.1016\/j.ejca.2024.115154","article-title":"Safety and efficacy of adjuvant FOLFOX\/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial","volume":"214","author":"Wang","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1200\/JCO-25-01737","article-title":"Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial","volume":"44","author":"Gelli","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Vauthey, J.N., Kawaguchi, Y., and Adam, R. (2022). Colorectal Liver Metastasis, Springer International Publishing.","DOI":"10.1007\/978-3-031-09323-4"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Engstrand, J., Nilsson, H., Stromberg, C., Jonas, E., and Freedman, J. (2018). Colorectal cancer liver metastases\u2014A population-based study on incidence, management and survival. BMC Cancer, 18.","DOI":"10.1186\/s12885-017-3925-x"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/SLA.0000000000000786","article-title":"Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?","volume":"261","author":"Dueland","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.suronc.2020.02.008","article-title":"Debulking surgery for colorectal liver metastases: Foolish or chance?","volume":"33","author":"Adam","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1432-2277.2008.00735.x","article-title":"Liver transplantation for primary and metastatic liver cancers","volume":"21","author":"Hoti","year":"2008","journal-title":"Transpl. Int."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","article-title":"Liver transplantation for nonresectable liver metastases from colorectal cancer","volume":"257","author":"Hagness","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/SLA.0000000000003404","article-title":"Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases","volume":"271","author":"Dueland","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/LVT.0000000000000746","article-title":"Optimizing liver transplant outcomes for colorectal liver metastases in the United States","volume":"32","author":"Sasaki","year":"2026","journal-title":"Liver Transpl."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Soomro, F.H., Kazmi, T.F., Ansar, M., Gulnaz, N., Arshad, R., and Aiste, G. (2026). Liver Transplantation as a Salvage Therapy Option in Colorectal Liver Metastases: Feasibility, Oncologic Outcomes, and Survival After Failure of Conventional Therapy-A Systematic Review and Meta-Analysis. Cancers, 18.","DOI":"10.3390\/cancers18081254"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/ajt.15682","article-title":"Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis","volume":"20","author":"Dueland","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2017.03.009","article-title":"Resection of colorectal liver metastases after second-line chemotherapy: Is it worthwhile? A LiverMetSurvey analysis of 6415 patients","volume":"78","author":"Adam","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"djx015","DOI":"10.1093\/jnci\/djx015","article-title":"Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Kalil, J.A., Krzywon, L., Zlotnik, O., Perrier, H., Petrillo, S.K., Chaudhury, P., Schadde, E., and Metrakos, P. (2024). Debulking Hepatectomy for Colorectal Liver Metastasis Conveys Survival Benefit. Cancers, 16.","DOI":"10.3390\/cancers16091730"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1001\/jama.2026.1929","article-title":"Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial","volume":"335","author":"Gootjes","year":"2026","journal-title":"JAMA"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Oppel, F., Gorner, M., and Sudhoff, H. (2020). The Potential of Tumor Debulking to Support Molecular Targeted Therapies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00801"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Abi-Jaoudeh, N., Ziemlewicz, T.J., White, S., Wah, T., and Cho, C. (2026). Histotripsy for Liver Tumor Ablation and Beyond: AJR Expert Panel Narrative Review. Am. J. Roentgenol., Epub ahead of print.","DOI":"10.2214\/AJR.26.34627"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamasurg.2024.2339","article-title":"Histotripsy\u2014A Novel and Intriguing Technique of Liver Ablation","volume":"160","author":"Rog","year":"2025","journal-title":"JAMA Surg."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.gassur.2024.05.038","article-title":"Histotripsy\u2014Hype or hope? Review of innovation and future implications","volume":"28","author":"Sandilos","year":"2024","journal-title":"J. Gastrointest. Surg."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"109898","DOI":"10.1016\/j.surg.2025.109898","article-title":"The first full year of histotripsy for liver tumors: Local tumor control and preliminary oncologic efficacy","volume":"191","author":"Wehrle","year":"2026","journal-title":"Surgery"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/02656736.2022.2112309","article-title":"First-in-man histotripsy of hepatic tumors: The THERESA trial, a feasibility study","volume":"39","author":"Serres","year":"2022","journal-title":"Int. J. Hyperth."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e233051","DOI":"10.1148\/radiol.233051","article-title":"The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors","volume":"312","author":"Wiggermann","year":"2024","journal-title":"Radiology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"103926","DOI":"10.1016\/j.eclinm.2026.103926","article-title":"Histotripsy for liver tumours: A systematic review and meta-analysis of current clinical evidence","volume":"95","author":"Wehrle","year":"2026","journal-title":"eClinicalMedicine"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3169\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:47:01Z","timestamp":1790848021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":148,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193169"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193169","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}